REG-4basebio Plc: Appointment of CCO

4BasebioAnnouncement

Today 07:00

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

4basebio PLC

("4basebio" or the "Company")

4basebio                                                                      
                                                                       
strengthens commercial leadership, promoting Christine Wolosin to Chief
Commercial Officer
*                                                                             
                                                          Seasoned
biotechnology commercial leader will drive global growth strategy             
                                                                              
                                  
*                                                                             
                                       Commercial team further bolstered by
promotions of James Vang and Jennifer Gelman to VP, Business Development and
VP, Marketing, respectively
CAMBRIDGE, UK, 3 March 2026 –                                               
                                                                              
      4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and
nucleic acids for next-generation therapeutics, announces the promotion of
Christine Wolosin to Chief Commercial Officer. Christine, who joined 4basebio
in September 2025 as Vice President, Business Development, will lead the
Company's global commercial strategy, business development initiatives, and
customer engagement as the Company scales its innovative synthetic DNA
platform to serve the rapidly growing cell and gene therapy, mRNA, and vaccine
markets.

Christine’s promotion follows the appointment of Dr Amy Walker as Chief
Executive Officer, replacing Dr Heikki Lanckriet. Christine will work closely
with Amy to execute 4basebio’s                                              
                                                  accelerated commercial
growth strategy, focusing on deepening penetration of the synthetic DNA market
as customers seek alternatives to plasmid DNA.

Christine brings more than 25 years of experience in the life sciences
industry, with a proven track record of building and scaling go-to-market
capabilities in the cell and gene therapy space. Prior to joining 4basebio,
she served as Vice President of Business Development at Emmes, where she led
the buildout of the North America commercial organisation to support growth in
biopharma innovator trials and later-phase studies. She established scalable,
globally aligned commercial processes and advanced Emmes’ strategic
positioning within the biopharma sector. Christine has also held senior global
commercial leadership roles at leading life sciences organisations including
TriLink BioTechnologies and Thermo Fisher Scientific, where she led the
go-to-market launches for a number of advanced therapy offerings, including
Thermo Fisher Scientific’s viral vector manufacturing expansion at its
flagship Plainville, Massachusetts facility.

Dr Amy Walker, Chief                                                          
                                                        Executive Officer of
4basebio, commented                                                           
                                                                         :    
                                                                              
                                                                              
   "4basebio is moving into an accelerated commercial phase as the Company
scales operations and builds partnerships across RNA, cell and gene therapy
and vaccine development. Since joining 4basebio, Christine has demonstrated an
ability to build strategic relationships within the nucleic acid manufacturing
space and a deep understanding of customer needs in the advanced therapy
sector. Her leadership and experience will be instrumental as we work to
establish 4basebio as the partner of choice for companies developing
next-generation therapeutics and vaccines."

Christine Wolosin, Chief Commercial Officer of 4basebio, commented:           
                                                                              
                                          "4basebio's proprietary synthetic
DNA platform addresses critical limitations of traditional plasmid-based
systems, offering biopharma partners key speed, purity and scalability
advantages. I have enjoyed working with the talented team at 4basebio to
accelerate partnerships with innovators in gene therapy, mRNA therapeutics,
and next-generation vaccines. The market opportunity is substantial, and we
are uniquely positioned to capture it."

To support the continued scaling of commercial operations, 4basebio has also
promoted James Vang to Vice President, Business Development and Jennifer
Gelman to Vice President, Marketing. James' promotion recognises his
significant contributions to 4basebio's commercial expansion since joining the
Company, while Jennifer’s reflects her leadership in establishing 4basebio's
market presence and brand positioning.

For further enquiries, please contact:

 4basebio PLC                                      +44 (0)12 2396 7943  
 Dr Amy Walker, CEO                                                     
                                                                        
 Cairn Financial Advisers LLP (Nominated Adviser)  +44 (0)20 7213 0880  
 Jo Turner / Sandy Jamieson / Ed Downes                                 
                                                                        
 Cavendish Capital Markets Limited (Joint Broker)  +44 (0)20 7220 0500  
 Geoff Nash / Nigel Birks                                               
                                                                        
 RBC Capital Markets (Joint Broker)                +44 (0)20 7653 4000  
 Kathryn Deegan / Matthew Coakes                                        
                                                                        
 ICR Healthcare (Media and Investor Relations)     +44 (0)203 707 5700  
 Mary-Jane Elliott / Jessica Hodgson                                    

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the
use of synthetic DNA to enable next-generation therapeutics and vaccines.
Through its proprietary enzymatic DNA synthesis platform, 4basebio produces
GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,
overcoming the limitations of plasmid-based systems. The company offers
application-specific DNA constructs tailored to the diverse needs of gene
therapies, genome editing, mRNA production, and DNA vaccines, helping partners
accelerate proof-of-concept studies and reach clinical milestones more
efficiently while maintaining the highest standards of safety and quality.

For more information, visit                                                   
                                                        4basebio.com          
                                   (https://www.4basebio.com/)                
                                             .



Copyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved